Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old~* Patients must have acute onset of ARDS, as defined by the American-European Consensus Conference (AECC) criteria for ARDS: (i) having an initiating clinical condition (pneumonia, aspiration, inhalation injury, sepsis, trauma, acute pancreatitis, etc.; (ii) bilateral infiltrates on frontal chest radiograph; (iii) absence of left atrial hypertension, a pulmonary capillary wedge pressure (PCWP) less than 18 mm Hg, or no clinical signs of left heart failure; (iv) severe hypoxemia (a PaO2/FIO2 \<200 mm Hg, regardless of FIO2 or positive end-expiratory pressure (PEEP)~* Be intubated and mechanically ventilated~* Have provided signed written informed consent from the patient or the patient's personal legal representative~Exclusion Criteria:~* Be a woman known to be pregnant or lactating~* Take part in another experimental treatment protocol (simultaneously)~* Brain death~* Terminal-stage cancer or other terminal disease~* Having do-not-resuscitate orders~* Being immune-compromised~* Receiving corticosteroids or immunosuppressive drugs~* Patients in whom more than 24 hours had elapsed after initially meeting the AECC ARDS criteria before consent and results of initial standard ventilator settings could be obtained.~* Have severe chronic obstructive pulmonary disease (COPD)~* Have congestive heart failure

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No dexamethasone (Type: NO_INTERVENTION): Patients will be treated with conventional treatment
- Dexamethasone (Type: ACTIVE_COMPARATOR): Conventional treatment plus dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).